Saturday, July 11, 2026

pharma · Lymphoma of B-cell origin · Malignant Solid Tumors

Genmab

Genmab A/S is a pharma organization headquartered in Valby, DK. Primary therapeutic focus areas include Lymphoma of B-cell origin, Malignant Solid Tumors, Metastatic or advanced malignant solid tumors, Non-Small Cell Lun

Carl Jacobsens Vej 30, 2500 Valby, DK HQ
2,847 Employees
EMA registrant Type
Company details
Status
Public
HQ
Carl Jacobsens Vej 30, 2500 Valby, DK
Employees
2,847
Programs
29
Drugs
56
Patents
0
Clinical program

GEN1042

Phase 1 · mab · Malignant Solid Tumor

GEN1042 for Malignant Solid Tumor is a Phase 1 program (mab) at Genmab A/S with 1 ClinicalTrials.gov record(s).

Internal code GCT1042-03

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Genmab A/S
Phase
Phase 1
Modality
mab
Indication
Malignant Solid Tumor
Status
active
Trials
1

Clinical trials